World journal of clinical pediatrics · 2026
Patient satisfaction and performance of the A8+ TouchCare Nano in children and adolescents with type 1 diabetes mellitus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kosta Konstantina, Grammatikopoulou Maria G, Toulia Ilektra, Smyrnaki Penelope, Paschalidou Eleni G, Vamvakis Anastasios, Bogiatzoglou Antonios, Tzimos Christos, Tsiroukidou Kyriaki
Аннотация
BACKGROUND: The role of automated insulin delivery systems in type 1 diabetes mellitus (T1DM) is constantly expanding, merging continuous glucose monitoring readings with a control algorithm and a continuous subcutaneous insulin infusion device, i.e. insulin pump.
AIM: To evaluate the effectiveness of a new, open and closed-loop insulin delivery system in children and adolescents with T1DM.
METHODS: Children and adolescents with T1DM (n = 28) were recruited from two pediatric endocrinology clinics situated in Thessaloniki and Crete (Greece), during the year 2025. The Medtrum A8+ TouchCare Nano system was used on all patients and comparison of glycemic control and treatment satisfaction were evaluated before and after the introduction of the new system.
RESULTS: The results showed increased patient satisfaction with the continuous subcutaneous insulin infusion, in particular when the closed-loop system was integrated. Participants were satisfied with most of the system's features, including the predictive low glucose suspend feature, aiming in preventing hypoglycemic episodes and the Auto Meal Handling feature, adjusting the carbohydrate content of each meal without necessitating carbohydrate counting. Time in range, glycosylated haemoglobin levels glucose management indicator, time above range, very high glucose levels, time in tight range and average blood glucose levels were improved after the introduction of the new system. The results remained similar even when closed/open loop systems were evaluated, or when the sample was divided in pre-pubertal/pubescent participants. No adverse events were recorded.
CONCLUSION: The results indicate the that Medtrum A8+ TouchCare Nano system is safe and effective in maintaining and improving glycemic control in children and adolescents with T1DM. More research on pediatric patients is required to further verify these results.
AIM: To evaluate the effectiveness of a new, open and closed-loop insulin delivery system in children and adolescents with T1DM.
METHODS: Children and adolescents with T1DM (n = 28) were recruited from two pediatric endocrinology clinics situated in Thessaloniki and Crete (Greece), during the year 2025. The Medtrum A8+ TouchCare Nano system was used on all patients and comparison of glycemic control and treatment satisfaction were evaluated before and after the introduction of the new system.
RESULTS: The results showed increased patient satisfaction with the continuous subcutaneous insulin infusion, in particular when the closed-loop system was integrated. Participants were satisfied with most of the system's features, including the predictive low glucose suspend feature, aiming in preventing hypoglycemic episodes and the Auto Meal Handling feature, adjusting the carbohydrate content of each meal without necessitating carbohydrate counting. Time in range, glycosylated haemoglobin levels glucose management indicator, time above range, very high glucose levels, time in tight range and average blood glucose levels were improved after the introduction of the new system. The results remained similar even when closed/open loop systems were evaluated, or when the sample was divided in pre-pubertal/pubescent participants. No adverse events were recorded.
CONCLUSION: The results indicate the that Medtrum A8+ TouchCare Nano system is safe and effective in maintaining and improving glycemic control in children and adolescents with T1DM. More research on pediatric patients is required to further verify these results.